Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions.
Stemedica has a team of experienced scientists, management and technicians to progress our proprietary technology.
Stemedica’s proprietary platform technology produces multiple progenitor cell products that meet exacting quality standards required for a cGMP licensed facility.
Stemedica is currently advancing clinical trials in the United States for several critical medical conditions.
Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke
SAN DIEGO, California – January 19, 2023. Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant, allogeneic mesenchymal stem cells (itMSC), announced today that it has initiated its “PHASE IIB/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,...
DARIUS ANDERSON TO JOIN STEMEDICA BOARD OF DIRECTORS
Respected and seasoned business leader, investor and political strategist offers multiple talents to stem cell technologies company SAN DIEGO, March 30, 2022 /PRNewswire/ -- Stemedica Cell Technologies, Inc. ("Stemedica"), a San Diego-based biotech company...
StemProtein Awarded U.S. Patent for Biodegradable Microneedle Device
Dissolvable Needles Allow Dermis Delivery of Proteins and Large Molecules SAN DIEGO — August 23, 2021 — StemProtein, LLC (a subsidiary of Stemedica Cell Technologies, Inc.) a leading manufacturer of physiologically balanced growth factors, exosomes, and...